(Q43690739)

25 November 2017

Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma (English)

1 reference

25 November 2017

Reynolds C

1

1 reference

25 November 2017

Ratanatharathorn V

2

1 reference

25 November 2017

Adams P

3

1 reference

25 November 2017

Braun T

4

1 reference

25 November 2017

Silver S

5

1 reference

25 November 2017

Ayash L

6

1 reference

25 November 2017

Carson E

7

1 reference

25 November 2017

Eisbruch A

8

1 reference

25 November 2017

Dawson LA

9

1 reference

25 November 2017

McDonagh K

10

1 reference

25 November 2017

Ferrara J

11

1 reference

25 November 2017

Uberti J

12

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

Bone Marrow Transplantation

25 November 2017

1 reference

25 November 2017

27

1 reference

25 November 2017

8

1 reference

25 November 2017

801-807

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703006

25 November 2017

0 references

cites work

High-dose melphalan for multiple myeloma: long-term follow-up data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): report of a workshop of the European group for Blood and Marrow Transplantation (EBMT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melph

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

Long-term follow-up after high-dose therapy for high-risk multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

7 January 2021

Treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

1 reference

7 January 2021

Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

7 January 2021

Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

7 January 2021

High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

7 January 2021

Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

7 January 2021

Impact of previous high-dose therapy on outcome after allografting for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

7 January 2021

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

7 January 2021

Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

7 January 2021

Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703006

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703006

1 reference

Dimensions Publication ID

25 November 2017

0 references

1 reference